Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis

Figures

• 

  FIGURE 1. Flowchart of data cleaning process for adverse event data of anthracycline for acute myeloid leukemia based on the FAERS database. FAERS, Food and Drug Administration Adverse Event Reporting System.

• 

  FIGURE 2. Forest plot and heatmap (top 30) of preferred terms induced by anthracycline for treating acute myeloid leukemia. BCPNN, Bayesian confidence propagation neural network; MGPS, multi-item gamma Poisson shrinker; PRR, proportional reported ratio; ROR, reporting odds ratio. Note: The number of reports differed substantially across anthracycline agents (e.g., epirubicin n = 15 vs. idarubicin n = 509). Estimates based on small case numbers may be unstable and should be interpreted with caution.

• 

  FIGURE 3. Forest plot and heatmap (top 30) of preferred terms induced by idarubicin (a), daunorubicin (b), doxorubicin (c), and epirubicin (d) for treating acute myeloid leukemia. BCPNN, Bayesian confidence propagation neural network; MGPS, multi-item gamma Poisson shrinker; PRR, proportional reported ratio; ROR, reporting odds ratio. Note: The number of reports differed substantially across anthracycline agents (e.g., epirubicin n = 15 vs. idarubicin n = 509). Estimates based on small case numbers may be unstable and should be interpreted with caution.

• 

  FIGURE 4. The cumulative risk curve of time to induce adverse events for anthracycline. Note: 1) The x-axis shows time (in days) on a base-10 logarithmic scale to highlight early events. 2) The number of reports differed substantially across anthracycline agents (e.g., epirubicin n = 15 vs. idarubicin n = 509). Estimates based on small case numbers may be unstable and should be interpreted with caution.

• 

  FIGURE 5. The cumulative risk curve of time to induce adverse events for anthracycline by age (a) and sex (b). Note: 1) The x-axis shows time (in days) on a base-10 logarithmic scale to highlight early events. 2) The number of reports differed substantially across anthracycline agents (e.g., epirubicin n = 15 vs. idarubicin n = 509). Estimates based on small case numbers may be unstable and should be interpreted with caution.